Taletrectinib for Non-Small Cell Lung Cancer
(TRUST-II Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing taletrectinib, a new drug, in patients with advanced lung cancer that have a specific genetic change. Taletrectinib is taken orally and aims to stop cancer growth by blocking this genetic change.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications, specifically those that are potent inhibitors or inducers of CYP3A4/5 or P-glycoprotein, and those that can prolong the QT interval, at least 14 days before starting the study treatment and while on treatment.
What makes the drug Taletrectinib unique for treating non-small cell lung cancer?
Research Team
Lian Li
Principal Investigator
AnHeart Therapeutics Inc.
Eligibility Criteria
Adults with advanced non-small cell lung cancer (NSCLC) that tests positive for ROS1 fusion can join this trial. They should have at least one measurable tumor, be able to follow the study plan and COVID-19 rules, and not be pregnant or breastfeeding. People who've had certain recent treatments or have serious health issues like heart disease, untreated brain metastases, active infections, or a history of significant lung problems are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive taletrectinib monotherapy in 21-day cycles, with some receiving combination therapy with carboplatin and pemetrexed for 4 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment, including long-term survival follow-up
Treatment Details
Interventions
- Taletrectinib
Taletrectinib is already approved in China for the following indications:
- ROS1-positive non-small cell lung cancer (NSCLC)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nuvation Bio Inc.
Lead Sponsor
AnHeart Therapeutics Inc.
Industry Sponsor